Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Clinical trial NCT02731729 · COMPLETED
Trial details
- NCT number
- NCT02731729
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-21
- Primary completion
- 2018-08-27
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.